Type to search

News

Allergan to Share New Data at ARVO 2021

Share
Allergan to Share New Data at ARVO 2021 | Pharmtech Focus

Allergan, an AbbVie (NYSE: ABBV) company, today announced that it will present new data, including real-world evidence, and patient-reported outcomes (PROs) for products across its eye care portfolio and pipeline at the ARVO (Association for Research in Vision and Ophthalmology) 2021 Annual Virtual Meeting (May 1-7).

“We are excited to present a range of data that will help us better understand not just how our portfolio performs in the clinic, but also the real-world experiences of our patients,” said Michael R. Robinson, M.D., vice president, global therapeutic area head, eye care, AbbVie. “The diversity of our data at ARVO 2021 demonstrates how Allergan Eye Care is advancing potential treatments for patients living with a number of difficult-to-treat eye diseases including presbyopia and retina diseases such as age-related macular degeneration.”

The company will present patient-reported outcomes for AGN-190584, an investigational therapy for the treatment of presbyopia. Recently the company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration based on data from the Phase 3 GEMINI 1 and GEMINI 2 clinical studies.

Data presented at the meeting will also include new analyses from the Phase 3 ARTEMIS studies examining the duration of intraocular pressure (IOP) lowering and biodegradation kinetics of DURYSTA™.

Additionally, real world data from the multicenter EXPAND study, evaluating 12-month outcomes of an investigation into a novel placement of the XEN® Gel Stent, will be presented at the meeting. The XEN® Gel Stent is currently approved only for ab-interno placement.

The ARVO 2021 Annual Virtual Meeting abstracts can be viewed at https://arvo2021.arvo.org/agenda.

Details about the presentations are as follows:

Abstract

Presentation Details

All Times EDT

Glaucoma

Extended Duration of IOP Lowering with Bimatoprost Implant in
a Phase 3 Open-label Extension Study

Paper session: Pharmacological intervention or
cellular mechanisms

Sunday, May 2

11:15 a.m. EDT

A Minipump Continuous Drug Infusion Dog Model System to
Identify Candidate Drugs and Drug Delivery Rates for
Intracameral IOP-lowering Implants

Poster session: Pharmacological intervention
and cellular mechanisms

Monday, May 3

11:15 a.m. EDT

Rate of Bimatoprost Implant Biodegradation in the Phase 3
ARTEMIS Studies

Paper session: Clinical Studies

Monday, May 3

11:15 a.m. EDT

Corneal Endothelial Cell Loss Associated with Selective Laser
Trabeculoplasty

Poster session: Ocular Blood Flow, Laser
Therapy, and IOP Measurements

Wednesday, May 5

2:45 p.m. EDT

A Retrospective Analysis: Visual Field Progression and Visual
Acuity following Administration of Brimonidine Drug Delivery
System

Poster session: Structure/Function, Visual
Fields, Psychophysics, and Electrophysiology

Monday, May 3

4:30 p.m. EDT

Retrospective, Multicenter, 12-month Evaluation of Ab-externo
XEN Gel Stent Placement: Real-world Data from the EXPAND
Study Group

Poster session: Surgery and Wound Healing I
and II

Wednesday, May 5

9:00 a.m. EDT

Presbyopia

Evaluating Vision-related Reading Ability With a de Novo PRO
Instrument in a Phase 3 Study of AGN-190584 (Pilocarpine
1.25%) for Presbyopia

Poster session: Refractive error, refraction,
accommodation and presbyopia

Thursday, May 6

11:15 a.m. EDT

Assessing Presbyopia Impacts and Coping Behaviors with a de

Novo PRO Instrument in a Phase 3 Study of AGN-190584
(Pilocarpine 1.25%)

Poster session: Refractive error, refraction,
accommodation and presbyopia

Thursday, May 6

11:15 a.m. EDT

Age-related Macular Degeneration

Duration of Effect of a Single Intravitreal Injection of a
Sustained-release Formulation of Abicipar Pegol Compared to
a Bolus Dose of Aflibercept in a Rabbit Model of Persistent
Retinal Vascular Leak

Poster session: AMD and retinal physiology

Wednesday, May 5

2:45 p.m. EDT

Developing Methotrexate-induced Immune Tolerance in a
Rabbit Model of Persistent Retinal Vascular Leak

Poster session: AMD and retinal physiology

Wednesday, May 5

2:45 p.m. EDT

Comparison of Visual Function in a Non-human Primate (NHP)
Model of Retinal Injury to Human Age-related Macular
Degeneration (AMD) Patients

Poster session: Psychophysics

Friday, May 7

2:15 p.m. EDT

Cytoprotective Effects of Brimonidine in an Induced Pluripotent
Stem Cell (iPSC)-derived Retinal Pigment Epithelium (RPE)
Model of Age-related Macular Degeneration (AMD)

Poster session: AMD and retinal physiology

Wednesday, May 5

2:45 p.m. EDT

Diabetic Macular Edema

Profile of Vascular Permeability Factors in Aqueous Humor of
Diabetic Macular Edema

Poster session: Diabetic macular edema

Friday, May 7

2:15 p.m. EDT

Tags:

People in this post:

Companies in this post:

You Might also Like

Related Stories

Next Up